Like Envision Pharma, Inc.

closed 4/15/2008 via PR Newswire

United BioSource Corporation, acquired Envision Pharma, Inc.

synopsis: United BioSource Corporation acquired Envision Pharma, a leading scientific communications and technology company. With a focus on the pharmaceutical and biotechnology industry, Envision integrates scientific communication services and targeted software applications.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Envision Pharma, Inc.
Envision Pharma is an innovative scientific communications and technology company providing commercially focused, strategically driven scientific and technology solutions to the pharmaceutical, biotechnology and device industries.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/11/2020 via BNC Analysis

A Consortium of 4 Buyers acquired Envision Pharma Group

synopsis: GHO Capital, together with Mubadala Investment Company, the Abu Dhabi-based sovereign investor, and including HarbourVest Partners and Northwestern Mutual, acquired the majority stake in Envision from Ardian SAS, a Paris-based global buyout firm. Envision Pharma Group is a global technology and scientific communications.
buyer: Mubadala Investment Company
buyer: HarbourVest Partners, LLC
buyer: GHO Capital
buyer: Northwestern Mutual
GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. Mubadala is a pioneering global investor. HarbourVest is an independent, global private markets asset manager. Northwestern Mutual helps families and businesses achieve financial security. "
target parent: Ardian
target: Envision Pharma Group
Envision Pharma Group is a global technology and scientific communications company serving pharmaceutical, biotechnology, and medical device companies. Envision is a leading provider of evidence-based communication services and industry-leading technology solutions through its iEnvision platform.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/13/2016 via PE Hub

Ardian, GHO Capital, acquired Envision Pharma, Inc.

synopsis: Leading middle-market private equity firm, The Halifax Group, announced that it has sold Envision Pharma Group to Ardian and GHO Capital. Envision is a recognized strategic partner for Medical Affairs teams within biopharma, providing scientific data communication services and industry-leading technology solutions.
buyer: Ardian
buyer: GHO Capital
Ardian is an independent private investment company with assets of US$55bn managed or advised in Europe, North America and Asia. Global Healthcare Opportunities, or GHO Capital, was founded in 2014 as a specialist healthcare investment adviser based in London. "
target parent: Halifax Group
target: Envision Pharma, Inc.
Envision is a recognized strategic partner for Medical Affairs teams within biopharma, providing scientific data communication services and industry-leading technology solutions.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/19/2013 via BusinessWire

Halifax Group, acquired Envision Pharma, Inc.

synopsis: The Halifax Group, a leading middle-market private equity firm, announced that it has acquired Envision Pharma, Inc. from a subsidiary of Express Scripts Holding Co. Envision is an innovative global technology and scientific communication company focused on the pharmaceutical, biotechnology and medical device industries.
buyer: Halifax Group
The Halifax Group is a private equity firm that invests between $10 and $40 million alongside owners and managers of established, growing and profitable companies that are leaders in their market niche. "
target parent: Express Scripts Inc.
target: Envision Pharma, Inc.
Envision Pharma, founded in 2001, is an innovative global technology and scientific communication company serving pharmaceutical, biotechnology and medical device companies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/1/2021 via BusinessWire

Instem, acquired The Edge Software Consultancy Ltd.

synopsis: Instem, a leading provider of IT solutions and services to the global life sciences market, has acquired The Edge Software Consultancy Ltd., a UK-based software company specializing in the pharmaceutical and biotechnology industry. The Edge focuses on improving the efficiency of drug discovery research and development.
buyer: Instem (AIM:INS:$38.90)
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide. "
target: The Edge Software Consultancy Ltd.
The Edge is a UK-based software company specializing in the pharmaceutical and biotechnology industry. The Edge focuses on improving the efficiency of drug discovery research and development. Their BioRails platform enables automated data capture over the entire research and development process.
price ($mm)
$7.88
rev ($mm)
$3
EBITDA ($mm)
EV / rev
3.1x
EV / EBITDA
closed 11/25/2020 via Company Press Release

Advarra, acquired Longboat Clinical Ltd.

synopsis: Advarra, the market leader in regulatory review solutions and clinical site technologies, is pleased to announce the acquisition of Longboat, an innovative provider of clinical trial technologies focused on site training, protocol compliance, and patient engagement.
buyer parent: Genstar Capital LLC
buyer: Advarra
Advarra, headquartered in Columbia, Md., provides institutional review board (IRB), institutional biosafety committee (IBC) and global research compliance services to clinical trial sponsors, CROs, hospital systems, academic medical centers and investigators. "
target: Longboat Clinical Ltd.
Longboat is an innovative provider of user-friendly, fully mobile clinical research technology solutions that take the complexity out of trials for site staff, patients, monitors, and study teams, making protocol compliance easy and instinctive.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/2/2020 via Company Press Release

Cytel Inc., acquired Laiya Consulting, Inc.

synopsis: Cytel Inc. has announced the acquisition of Laiya Consulting, a drug development solutions company specializing in Bayesian adaptive trial designs and implementation. Laiya pioneered the delivery of trial design software using SaaS, which aligns with Cytel’s goal of making all of its design software available as a cloud-based service.
buyer parent: New Mountain Capital, LLC
buyer: Cytel Inc.
Cytel provides statistical software for clinical trials. Cytel provides an understanding of software tools that solve statistical problems and that meet the highest standards of reliability, technical documentation and customer support. "
target: Laiya Consulting, Inc.
Founded in 2010, Laiya Consulting has supported drug developers to drive success rates and maximize portfolio returns through the design and implementation of Bayesian adaptive trials, robust clinical strategies, and integrated software platforms.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/17/2019 via Company Press Release

Nordic Capital, will acquire Aris Global LLC

synopsis: Nordic Capital, a leading private equity investor in the Nordic region, will be acquiring ArisGlobal, a visionary technology company that has successfully developed a next-generation platform that uses advanced cognitive computing and machine learning to automate all core functions of drug safety, regulatory compliance and medical affairs.
buyer: Nordic Capital
Nordic Capital is a leading private equity investor in the Nordic region with a resolute commitment to creating stronger, sustainable businesses through operational improvement and transformative growth. "
target: Aris Global LLC
ArisGlobal is transforming the way most successful life sciences companies develop breakthroughs. Their end-to-end drug development technology platform, LifeSphere, integrates their proprietary Nava cognitive computing engine to automate all core functions of the drug development lifecycle.
price ($mm)
$700
rev ($mm)
$100
EBITDA ($mm)
EV / rev
7.0x
EV / EBITDA
closed 5/17/2012 via PR Newswire

Accelrys Software Inc., purchased Hit Explorer Operating System (HEOS) from SCYNEXIS, Inc.

synopsis: Accelrys, Inc. announced that it has purchased the Web-based Hit Explorer Operating System (HEOS) from SCYNEXIS, Inc. HEOS enables more efficient and streamlined drug discovery collaborations, particularly for organizations leveraging academic departments, research institutes and contract research organizations in externalized R&D projects.
buyer: Accelrys Software Inc. (ACCL:$166.25)
Accelrys, Inc. is a leading scientific enterprise R&D software and services company that supports industries and organizations that rely on scientific innovation to differentiate themselves. Headquartered in San Diego, Calif., Accelrys employs more than 200 full-time PhD scientists. "
seller: SCYNEXIS, Inc.
HEOS® is a comprehensive web-based drug research information management software platform that supports geographically-distributed scientists and facilitates collaboration. It is heavily used by users around the world including large pharmaceutical companies and biotechnology companies.
price ($mm)
$4.50
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/30/2021 via BNC Analysis

CSAM Health AS, acquired MedSciNet

synopsis: CSAM Health Group AS, the leading provider of niche eHealth solutions in the Nordics, announced that they have acquired MedSciNet AB, a provider of benchmark eHealth solutions within clinical research.
buyer: CSAM Health AS (OB:CSAM:$30.36)
CSAM is a leading Norwegian company in the specialized eHealth market with a unique blend of best in class innovative technology, and outstanding human skills. Their diverse portfolio of software solutions enables healthcare providers to access relevant clinical information at the point of care. "
target: MedSciNet
MedSciNet is a Stockholm based company specialising in design and development of web applications and on-line database systems for clinical trials and studies, quality registries, medical bio-banks, and other solutions within the medical field.
price ($mm)
$2.88
rev ($mm)
$2
EBITDA ($mm)
EV / rev
1.7x
EV / EBITDA
announced 5/27/2021 via PR Newswire

Thoma Bravo, LLC, will acquire Greenphire, Inc

synopsis: Thoma Bravo, a leading private equity investment firm focused on the software and technology-enabled services sector, has reached an agreement to acquire Greenphire, the global leader in financial lifecycle management software for clinical trials, from The Riverside Company.
buyer: Thoma Bravo, LLC
Thoma Bravo is a leading private equity firm focused on the software and technology-enabled services sectors. Thoma Bravo partners with a company’s management team to implement operating best practices, invest in growth initiatives and make acquisitions intended to accelerate revenue and earnings. "
target parent: The Riverside Company
target: Greenphire, Inc
Greenphire is the leader in global clinical trial financial process automation. Greenphire's best-in-class solutions optimize clinical trial performance by streamlining payment and logistical workflows from sponsors and CROs to sites and patients.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/19/2021 via GlobeNewswire

Scarritt Group Inc., acquired TrialTech Medical Inc.

synopsis: Scarritt Group Inc., a technology-enabled leader in the planning and execution of meetings for Investigators and Coordinators of clinical trials, has acquired TrialTech Medical Inc, a leader in the application of cloud- based software and artificial intelligence enabled digital marketing for the recruitment of eligible subjects for clinical trials.
buyer: Scarritt Group Inc.
Scarritt Group is a technology-enabled, full service meeting planning and logistics company specializing in delivering clinical trial meetings worldwide. "
target: TrialTech Medical Inc.
TrialTech Medical is a software and services company supporting the pharmaceutical, biotechnology and medical device industries. They work in coordination with their clients' medical and clinical operations teams to optimize the process of clinical trial planning, recruitment and enrollment.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/20/2019 via BNC Analysis

Monterro, acquired Viedoc

synopsis: Monterro, the leading B2B software investor in the Nordics, has acquired a majority stake in Viedoc, a modern and sophisticated electronic data capture (EDC) system. Viedoc enables researchers to gather and evaluate clinical trial data more efficiently.
buyer: Monterro
Sweden-based Monterro is the leading B2B software investor in the Nordics, with a mission to turn software companies into market leaders. With operational experience from successfully developing and running companies, Monterro actively supports its portfolio companies in all aspects of growth. "
target: Viedoc
Viedoc is a modern and sophisticated electronic data capture (EDC) system. Viedoc enables researchers to gather and evaluate clinical trial data more efficiently. Their powerful EDC system has been used in over 2000 trials in more than 75 countries in all therapeutic areas and clinical phases.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/24/2019 via BNC Analysis

TrialScope, acquired Clinical Trial Connect, LLC

synopsis: TrialScope has acquired Clinical Trial Connect, a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. As part of the acquisition, founder Mike Wenger will share his technological expertise as part of the TrialScope team.
buyer: TrialScope
TrialScope is the global leader in clinical trial transparency and compliance. TrialScope's tools and systems enable their customers to improve their clinical trial process, mitigate registry and lifecycle risk, and ultimately achieve greater business success. "
target: Clinical Trial Connect, LLC
Clinical Trial Connect is a platform used by disease foundations and advocacy groups that connects their community members to relevant clinical trials. Clinical Trial Connect was founded by Mike Wenger, who developed his own algorithm for matching patients to clinical trials.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/28/2019 via BNC Analysis

JLL Partners, Water Street Healthcare Partners, acquired THREAD Research

synopsis: Water Street Healthcare Partners and JLL Partners have acquired Orange County, California-based THREAD, a provider of technology that enables virtual research approaches to modernize clinical studies and registries.
buyer: JLL Partners
buyer: Water Street Healthcare Partners
JLL Partners is a middle-market private equity firm with a 30-year track record of building and transforming businesses. Water Street is a strategic investor focused exclusively on healthcare. The firm has a strong record of building market-leading companies across key growth sectors in healthcare. "
target: THREAD Research
THREAD is a virtual research platform used by biopharma, CROs, non-profit researchers, and life science organizations to capture global clinical study data in between, as well as during and instead of clinic visits.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 7/17/2019 via GlobeNewswire

Anju Software, will acquire OmniComm Systems, Inc.

synopsis: Anju Software, a leading provider of comprehensive software solutions to the life sciences industry, will be acquiring OmniComm, a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services.
buyer parent: ABRY Partners, LLC
buyer: Anju Software
Anju Software, Inc. is a leading provider of comprehensive software solutions to the life sciences industry that provides an integrated platform spanning clinical operations, medical affairs, and commercial divisions, including integrated data intelligence. "
target: OmniComm Systems, Inc. (OTCPK:OMCM:$14,891.70)
OmniComm is a healthcare technology company that provides web-based electronic data capture and eClinical solutions and related value-added services to pharmaceutical and biotech companies, contract research organizations, and other clinical trial sponsors.
price ($mm)[EV]
$72 [$81]
rev ($mm)
$25
EBITDA ($mm)
$2
EV / rev
3.4x
EV / EBITDA
46.2x
announced 6/12/2019 via BusinessWire

Dassault Systemes, will acquire Medidata

synopsis: Dassault Systèmes, a provider of solutions that transform the way products are designed, provided and supported, will be acquiring Medidata, a provider of a platform for clinical development, commercial, and real-world data.
buyer: Dassault Systemes (ENXTPA:DSY:$5,323.17)
Based in France, Dassault Systèmes provides clients with virtual universes to imagine sustainable innovations. Its solutions transform the way products are designed, produced, and supported. They foster social innovation, expanding possibilities for the virtual world to improve the real world. "
target: Medidata (MDSO:$660.00)
Medidata is leading the digital transformation of life science, with a platform for clinical development, commercial, and real-world data. Powered by artificial intelligence, Medidata helps accelerate value, minimize risk and optimize outcomes.
price ($mm)[EV]
$5,825 [$5,822]
rev ($mm)
$660
EBITDA ($mm)
$81
EV / rev
8.8x
EV / EBITDA
72.2x
closed 4/10/2019 via BNC Analysis

TriNetX, acquired Custodix N.V.

synopsis: TriNetX has acquired Custodix, a Belgian-based provider of clinical trial patient recruitment solutions. TriNetX is a global health research network that has revolutionised clinical research. Custodix is a provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance.
buyer: TriNetX
TriNetX is the global health research network enabling healthcare organizations, biopharma and CROs to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. "
target: Custodix N.V.
Custodix is a Belgian provider of clinical trial patient recruitment solutions offering a range of solutions for ensuring compliance with European and US data protection legislation and security best practices.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/17/2018 via Company Press Release

Oracle Corporation, will acquire GoBalto

synopsis: Oracle announced that it has entered into an agreement to acquire goBalto, which delivers leading cloud solutions to accelerate clinical trials by streamlining and automating the selection and set up of the best performing clinical research sites to conduct trials.
buyer: Oracle Corporation (ORCL:$39,766.00)
Oracle is a computer technology corporation developing and marketing computer hardware systems and enterprise software products. By eliminating complexity and simplifying IT, Oracle enables its customers to accelerate innovation and create added value for their customers. "
target: GoBalto
goBalto, Inc. is an award winning, venture backed group of industry veterans that creates simple, focused software for the global drug trial industry. Its products offer drug trial sponsors and clinical research organizations the fastest, easiest possible way to start clinical studies on the web.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/21/2018 via BusinessWire

Anju Software, acquired Sylogent

synopsis: Anju Software Inc., a life sciences software platform backed by Providence Equity Partners, has acquired Sylogent. Sylogent delivers cloud based state of the art software solutions and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market.
buyer parent: Providence Equity Partners Inc.
buyer: Anju Software
Anju Software is a life sciences enterprise software platform focused on delivering exceptional business application solutions. Anju was founded by professionals with deep software domain expertise and a track record of building software platforms through strategic acquisitions and organic growth. "
target: Sylogent
Sylogent delivers software and business services to the pharmaceutical industry focused specifically on the information required to bring a product to market. They ensure the timely completion of critical information, maximize compliance goals and reduce risk management liability.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/24/2021 via BNC Analysis

Envision Pharma Group, acquired doDOC Corp.

synopsis: Envision Pharma Group, a leading global technology-enabled scientific communications company, is pleased to announce the acquisition of doDOC Corp., a leader in document collaborative review, editing, and authoring. doDoc was founded by MIT alumni in 2015 in Boston, MA, and with a European base in Coimbra, Portugal.
buyer parent: GHO Capital
buyer: Envision Pharma Group
Envision Pharma Group is a global technology and scientific communications company serving pharmaceutical, biotechnology, and medical device companies. Envision is a leading provider of evidence-based communication services and industry-leading technology solutions through its iEnvision platform. "
target: doDOC Corp.
Founded by MIT alumni in 2015 in Boston, MA, and with a European base in Coimbra, Portugal, doDOC has the mission to transform the way life sciences teams write and review their documents, offering cloud-based software for enterprise documentation.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/11/2020 via BNC Analysis

A Consortium of 4 Buyers acquired Envision Pharma Group

synopsis: GHO Capital, together with Mubadala Investment Company, the Abu Dhabi-based sovereign investor, and including HarbourVest Partners and Northwestern Mutual, acquired the majority stake in Envision from Ardian SAS, a Paris-based global buyout firm. Envision Pharma Group is a global technology and scientific communications.
buyer: Mubadala Investment Company
buyer: HarbourVest Partners, LLC
buyer: GHO Capital
buyer: Northwestern Mutual
GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. Mubadala is a pioneering global investor. HarbourVest is an independent, global private markets asset manager. Northwestern Mutual helps families and businesses achieve financial security. "
target parent: Ardian
target: Envision Pharma Group
Envision Pharma Group is a global technology and scientific communications company serving pharmaceutical, biotechnology, and medical device companies. Envision is a leading provider of evidence-based communication services and industry-leading technology solutions through its iEnvision platform.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/9/2020 via BNC Analysis

Envision Pharma Group, acquired 90Ten

synopsis: Global healthcare communications consultancy 90TEN has been acquired by Envision Pharma Group, a global provider of evidence-based communication services and industry-leading technology solutions. The acquisition of 90TEN extends Envision’s footprint in patient engagement and medical communications with its behavioral science methodology.
buyer parent: Ardian
buyer: Envision Pharma Group
Envision Pharma Group is a global technology and scientific communications company serving pharmaceutical, biotechnology, and medical device companies. Envision is a leading provider of evidence-based communication services and industry-leading technology solutions through its iEnvision platform. "
target: 90Ten
90TEN is a global healthcare communications consultancy that aims to make people healthier and happier through education and communications. The company provides PR, medical communications, and patient advocacy services that use behavioral science methodologies to maximize brand and health outcomes.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/13/2016 via PE Hub

Ardian, GHO Capital, acquired Envision Pharma, Inc.

synopsis: Leading middle-market private equity firm, The Halifax Group, announced that it has sold Envision Pharma Group to Ardian and GHO Capital. Envision is a recognized strategic partner for Medical Affairs teams within biopharma, providing scientific data communication services and industry-leading technology solutions.
buyer: Ardian
buyer: GHO Capital
Ardian is an independent private investment company with assets of US$55bn managed or advised in Europe, North America and Asia. Global Healthcare Opportunities, or GHO Capital, was founded in 2014 as a specialist healthcare investment adviser based in London. "
target parent: Halifax Group
target: Envision Pharma, Inc.
Envision is a recognized strategic partner for Medical Affairs teams within biopharma, providing scientific data communication services and industry-leading technology solutions.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/19/2013 via BusinessWire

Halifax Group, acquired Envision Pharma, Inc.

synopsis: The Halifax Group, a leading middle-market private equity firm, announced that it has acquired Envision Pharma, Inc. from a subsidiary of Express Scripts Holding Co. Envision is an innovative global technology and scientific communication company focused on the pharmaceutical, biotechnology and medical device industries.
buyer: Halifax Group
The Halifax Group is a private equity firm that invests between $10 and $40 million alongside owners and managers of established, growing and profitable companies that are leaders in their market niche. "
target parent: Express Scripts Inc.
target: Envision Pharma, Inc.
Envision Pharma, founded in 2001, is an innovative global technology and scientific communication company serving pharmaceutical, biotechnology and medical device companies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/15/2008 via PR Newswire

United BioSource Corporation, acquired Envision Pharma, Inc.

synopsis: United BioSource Corporation acquired Envision Pharma, a leading scientific communications and technology company. With a focus on the pharmaceutical and biotechnology industry, Envision integrates scientific communication services and targeted software applications.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Envision Pharma, Inc.
Envision Pharma is an innovative scientific communications and technology company providing commercially focused, strategically driven scientific and technology solutions to the pharmaceutical, biotechnology and device industries.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 6/19/2013 via BusinessWire

Halifax Group, acquired Envision Pharma, Inc.

synopsis: The Halifax Group, a leading middle-market private equity firm, announced that it has acquired Envision Pharma, Inc. from a subsidiary of Express Scripts Holding Co. Envision is an innovative global technology and scientific communication company focused on the pharmaceutical, biotechnology and medical device industries.
buyer: Halifax Group
The Halifax Group is a private equity firm that invests between $10 and $40 million alongside owners and managers of established, growing and profitable companies that are leaders in their market niche. "
target parent: Express Scripts Inc.
target: Envision Pharma, Inc.
Envision Pharma, founded in 2001, is an innovative global technology and scientific communication company serving pharmaceutical, biotechnology and medical device companies.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/18/2011 via BNC Analysis

United BioSource Corporation, acquired Arrowhead Electronic Healthcare

synopsis: Bracket, a division of United BioSource Corp. has acquired Arrowhead Electronic Healthcare, a privately-held electronic patient-reported outcome (ePRO) technologies company. Its ePRO-LOG software platform is used in more than 60 countries on smart phones, tablet computers, the Web and text-messaging apps.
buyer parent: Medco Health Solutions, Inc.
buyer: United BioSource Corporation
United BioSource Corporation (UBC) is a global scientific and medical affairs organization comprised of over 1,400 colleagues who design and execute product development and commercialization programs for clients throughout the industry. "
target: Arrowhead Electronic Healthcare
Arrowhead Electronic Healthcare is an electronic patient-reported outcome (ePRO) technologies company. The company advances patient-centric medical decisions by pioneering software solutions that capture and report real-time patient experiences using smartphones, Web, Tablet computers, and SMS.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/10/2009 via BusinessWire

United BioSource Corporation, acquired Cognitive Drug Research, Ltd.

synopsis: United BioSource Corporation (UBC) announced the acquisition of Cognitive Drug Research, Ltd. (CDR), the leader in computerized cognitive testing for clinical trials. The CDR System is the most widely used computerized cognitive testing system in the world: it is used in more than 1000 trials encompassing approximately 50 different disease areas.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Cognitive Drug Research, Ltd.
Cognitive Drug Research, Ltd. (CDR) is the world leader in automated cognitive function assessment in phase I through phase IV clinical trials. Founded by Keith Wesnes in 1986, CDR’s proprietary cognitive assessment system can be administered to virtually any patient population in any environment.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 5/18/2009 via BusinessWire

United BioSource Corporation, acquired Healthcare Project Management

synopsis: United BioSource Corporation has announced the acquisition of HPM (Geneva) SA, a Geneva, Switzerland-based provider of drug safety and pharmacovigilance services, further extending UBC’s reach into the European market.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Healthcare Project Management
Healthcare Project Management (HPM) is a contract research organization founded in 1997 to provide clinical research services to industry as well as academia. Our core services are drug safety, medical writing and scientific consultancy.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/15/2008 via PR Newswire

United BioSource Corporation, acquired Envision Pharma, Inc.

synopsis: United BioSource Corporation acquired Envision Pharma, a leading scientific communications and technology company. With a focus on the pharmaceutical and biotechnology industry, Envision integrates scientific communication services and targeted software applications.
buyer parent: Oak Investment Partners
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: Envision Pharma, Inc.
Envision Pharma is an innovative scientific communications and technology company providing commercially focused, strategically driven scientific and technology solutions to the pharmaceutical, biotechnology and device industries.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/7/2006 via Company Press Release

United BioSource Corporation, acquired BioCor LLC

synopsis: United BioSource Corporation acquired BioCor LLC, a provider of clinical data services to the pharmaceutical and biotechnology industries. BioCor delivers dedicated clinical data services and medical writing capabilities to support the regulatory approval process for new drugs.
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: BioCor LLC
BioCor provides clinical data services, biostatistics, and medical writing to the pharmaceutical and biotechnology industries. The company is based in Yardley, Pennsylvania.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 9/6/2006 via

United BioSource Corporation, acquired BioNiche Global Learning

synopsis: United BioSource Corporation has acquired Bioniche Global Learning, a McLean, Virginia-based provider of training and education services to the pharmaceutical and biotechnology industries. Bioniche specializes in developing and implementing international programs for training health care professionals who serve as investigators in clinical research
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: BioNiche Global Learning
Bioniche Global Learning provides domestic and international rater training and other clinical trial and CME related educational services to the pharmaceutical and biotechnology industries. The Company specializes in psychiatry and other central nervous system diseases.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/24/2006 via PR Newswire

United BioSource Corporation, purchased iLearn, an Advanced Learning Management System from IQ Consultancy Group

synopsis: United BioSource Corporation (UBC) today announced the acquisition of iLearn, an Advanced Learning Management System developed by the UK-based provider of eContent solutions, IQ Consultancy. The robust web-based technology allows UBC to offer new enterprise learning services to pharmaceutical and biotechnology clients.
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
seller: IQ Consultancy Group
IQ Consultancy Group is an independent provider of eContent solutions, knowledge management solutions and project management services for e-Business. The company is based in Warrington, United Kingdom.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/17/2006 via PR Newswire

United BioSource Corporation, acquired MetaWorks, Inc.

synopsis: United BioSource Corporation (UBC) today announced the acquisition of MetaWorks, Inc., a leading provider of systematic reviews and meta-analyses to inform development, marketing, and regulatory decision-making regarding health care products and services.
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: MetaWorks, Inc.
MetaWorks Inc. has gained a reputation as one of the healthcare industry's most expert and reliable sources for Evidence-Based Medical Information and technology. MetaWorks is a leading provider of systematic reviews, meta-analyses and other evidence-based-information services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/20/2004 via BusinessWire

United BioSource Corporation, acquired MEDTAP International, Inc.

synopsis: United BioSource Corp. formed in early 2003 to provide science and evidence based services and information to the pharmaceutical and life sciences industries, announced that it has acquired MEDTAP International, Inc., a Bethesda, Md.-based provider of health economics and outcomes research services for the pharmaceutical and biotechnology industry.
buyer: United BioSource Corporation
United BioSource Corporation accelerates the generation, analysis and communication of real world evidence by integrating scientific and operational expertise with innovative technology solutions to support global development and commercialization of medical products for life science companies. "
target: MEDTAP International, Inc.
MEDTAP(R) International, Inc. is a global health services research firm that conducts patient reported outcomes studies, economic evaluation and modeling studies, policy research and analysis for pharmaceutical companies, managed care organizations, biotechnology firms, medical device and diagnosti
price ($mm)
$14
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/14/2009 via BusinessWire

NexMed, Inc., acquired Bio-Quant, Inc.

synopsis: NexMed, Inc., a developer of products based on the NexACT® technology, announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.
buyer: NexMed, Inc. (NEXM:$0.00)
NexMed is an innovative drug developer that is leveraging its proprietary NexACT® drug delivery technology to produce a host of new medical treatments. NexMed’s drugs address a variety of health conditions, such as nail fungus, sexual disorders and more. "
target: Bio-Quant, Inc.
Founded in 1999, Bio-Quant is the largest specialty CRO based in San Diego and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models specializing in oncology, inflammation, immunology, and metabolic diseases, including diabetes.
price ($mm)[EV]
$13 [$13]
rev ($mm)
$5
EBITDA ($mm)
EV / rev
2.5x
EV / EBITDA
closed 11/30/2009 via BusinessWire

PPD, Inc., acquired BioDuro, LLC

synopsis: PPD, Inc. announced it has completed its acquisition of BioDuro LLC, a drug discovery outsourcing company focused on integrated drug discovery programs and services. With this acquisition, PPD now employs more than 1,400 in Asia Pacific and nearly 1,000 people in China.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: BioDuro, LLC
BioDuro is a US-based, fully-integrated, end-to-end global life science outsourcing services company with a team of over 630 in Beijing, China. Our priority is providing the highest quality, FDA-compliant services at an affordable cost.
price ($mm)
$49
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 10/28/2009 via PR Newswire

Alpha Analytical, will acquire Boston Analytical

synopsis: Alpha Analytical is announcing the completion of the acquisition of Boston Analytical, Inc. Established in 1987, Boston Analytical is a registered, cGMP compliant contract testing laboratory providing quality analytical and microbiological testing services to the pharmaceutical, biotech, device, cosmetic and nutritional product industries.
buyer: Alpha Analytical
Alpha Analytical, Inc. provides full-service environmental laboratory solutions for the most demanding industrial and commercial applications in the U.S. and abroad. Alpha Analytical is the largest environmental laboratory in New England and among the top 18 laboratories in the country. "
target: Boston Analytical
Boston Analytical is committed to providing quality Analytical and Microbiological testing services to pharmaceutical companies worldwide in support of their Product Development, Release and Stability Testing objectives.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2009 via Company Press Release

J O Hambro Capital Management Limited, acquired Celsis International

synopsis: Chicago-based Celsis International, a leading global life sciences company, announces that it has been acquired by UK-based private equity firm J O Hambro and will de-list from the London Stock Exchange (LSE) and operate as a privately held company.
buyer: J O Hambro Capital Management Limited
J O Hambro Capital Management, the London-based boutique investment firm, offers an alternative to the large traditional fund management firms that have dominated the market for many years. "
target: Celsis International
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries through our three divisions: Rapid Detection, Analytical Services and In Vitro Technologies.
price ($mm)[EV]
$55 [$52]*
rev ($mm)
$42
EBITDA ($mm)
$12
EV / rev
1.9x
EV / EBITDA
6.3x
closed 7/16/2009 via PR Newswire

Water Street Healthcare Partners, acquired AAIPharma Services

synopsis: Water Street Healthcare Partners, a leading private equity firm focused exclusively on the health care industry, announced that it has acquired the Pharmaceutical Development division from AAIPharma Inc.
buyer: Water Street Healthcare Partners
Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. "
target parent: AAIPharma Inc.
target: AAIPharma Services
AAIPharma Services serves more than 300 large pharmaceutical and biotechnology companies. Its team of 450 scientists and professionals specialize in services that encompass the entire process of pharmaceutical drug development from discovery through commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/1/2009 via Reuters

INC Research, Inc., will purchase Late Stage Research Unit from MDS, Inc.

synopsis: MDS Inc has announced that it planns to narrow its contract research focus by selling its late stage operations and central laboratory divisions to Contract Research Organization INC Research, Inc.
buyer: INC Research, Inc. (SYNH:$4,730.38)
INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting Phase I- Phase IV clinical development programs of the highest integrity. "
seller: MDS, Inc. (MDZ:$231.00)
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
price ($mm)
$45
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

ChemRar High-Tech Center, acquired Prudentas, LLC

synopsis: ChemDiv, a global chemistry-driven contract research organization, announced that its ChemRar High Tech Center has acquired Prudentas LLC, one of the leading CRO companies conducting high quality Phase I - Phase IV studies in Eastern Europe.
buyer parent: ChemDiv, Inc.
buyer: ChemRar High-Tech Center
The ChemRar High-Tech Center is a unique pharma and biotechnology complex founded by innovative life science organizations in Russia. ChemRar's component companies are engaged in discovering, developing and commercializing novel drugs for partners in Russia and worldwide. "
target: Prudentas, LLC
Prudentas is a Russian Clinical Contract Research Organization founded by and consisting of highly qualified clinical research professionals with extensive experience of working previously together as a team.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

Chiltern International Inc., acquired Vigiun

synopsis: Chiltern International Limited, a global Clinical Research Organization (CRO) providing clinical development and staffing services in Europe, the Americas and India, announced the acquisition of Vigiun, a full service Clinical Research Organization located in Sao Paulo, Brazil.
buyer: Chiltern International Inc.
Chiltern is a global CRO with experience running and staffing international Phase I to Phase IV clinical trials. Chiltern’s services include: Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. "
target: Vigiun
Vigiun is a full service clinical research organization located in Sao Paulo, Brazil.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/29/2009 via BNC Analysis

JLL Partners, acquired Patheon, Inc.

synopsis: JLL Partners Inc. has become the majority shareholder of Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry.
buyer: JLL Partners
Founded in 1988, JLL Partners is among the leading private equity investment firms in the country. Since inception, we have managed a series of private equity funds aggregating approximately $4 billion in committed capital. "
target: Patheon, Inc.
Patheon Inc. is a leading provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon provides products and services to more than three hundred of the world's leading pharmaceutical and biotechnology companies.
price ($mm)[EV]
$89 [$300]*
rev ($mm)
$628
EBITDA ($mm)
$82
EV / rev
1.0x
EV / EBITDA
7.4x
closed 2/26/2009 via PR Newswire

ChanTest Corporation, acquired Applied Cell Sciences

synopsis: The leading experts in ion channels and G-protein coupled receptors - key to drug discovery, development, and safety - are now united. ChanTest, the leading provider of ion channel testing services and validated cell lines, announced that it has acquired Rockville, Maryland-based Applied Cell Sciences. ACS is a contract research organization.
buyer: ChanTest Corporation
ChanTest has developed the world’s most complete library of validated human ion channel-expressing cell lines to serve all the ion channel needs of its pharmaceutical and biotech customers. "
target: Applied Cell Sciences
Applied Cell Sciences delivers high throughput screening reagents and reagent-development services for drug discovery research.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 2/6/2009 via BusinessWire

WIL Research Laboratories, LLC, acquired Midwest BioResearch, LLC

synopsis: WIL Research Laboratories, LLC and WIL Research Holding Company, Inc. announce the acquisition of Midwest BioResearch, LLC. Together, Midwest BioResearch and WIL Research shall integrate their service offerings through scientific collaboration, sharing of best practices and marketing.
buyer: WIL Research Laboratories, LLC
WIL Research Laboratories, LLC is a contract research organization that provides an interdisciplinary approach to non-clinical toxicology, pharmacology, metabolism and both clinical and non-clinical bioanalytical services. "
target: Midwest BioResearch, LLC
Midwest BioResearch, LLC was founded in 2003 by scientists, directors and managers from major pharmaceutical companies to provide drug disposition and toxicology services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 9/25/2017 via BusinessWire

Konica Minolta, Inc., will acquire Invicro, LLC

synopsis: Konica Minolta, Inc. and Boston-based Invicro LLC announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development.
buyer: Konica Minolta, Inc. (TSE:4902:$8,793.96)
Konica Minolta, Inc. is a Japanese technology company headquartered in Tokyo. The company manufactures business and industrial imaging products, including copiers, laser printers, multi-functional peripherals (MFPs) and digital print systems for the production printing market. "
target: Invicro, LLC
Invicro is a leading provider of imaging services and software for research and drug development. Headquartered in Boston, Massachusetts, Invicro LLC was founded in 2008 with the mission of improving the role and function of imaging in drug discovery and development across all therapeutic areas.
price ($mm)
rev ($mm)
$106
EBITDA ($mm)
$17
EV / rev
0.0x
EV / EBITDA
0.0x
closed 8/16/2017 via BusinessWire

Evotec BioSystems GmbH, acquired Aptuit, Inc.

synopsis: Evotec announced that it has successfully completed the acquisition of Aptuit, a partner research organisation for integrated outsourced drug discovery and development solutions. This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation.
buyer: Evotec BioSystems GmbH (XTRA:EVT:$226.46)
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. "
target parent: Welsh, Carson, Anderson & Stowe
target: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators.
price ($mm)
$300
rev ($mm)
$93
EBITDA ($mm)
$12
EV / rev
3.2x
EV / EBITDA
25.8x
announced 6/20/2017 via Company Press Release

Pamplona Capital Management LLP, will acquire PAREXEL International Corporation

synopsis: Pamplona Capital Management, LLP has entered into a definitive agreement to acquire all of the outstanding shares of PAREXEL International Corporation, a leading global biopharmaceutical services provider. PAREXEL provides a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services.
buyer: Pamplona Capital Management LLP
Pamplona Capital Management is a London, New York, and Boston-based specialist investment manager established in 2005 that provides an alternative investment platform across private equity, fund of hedge funds, and single-manager hedge fund investments. "
target: PAREXEL International Corporation (PRXL:$1,939.36)
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.
price ($mm)[EV]
$4,508 [$4,923]
rev ($mm)
$2,097
EBITDA ($mm)
$343
EV / rev
2.4x
EV / EBITDA
14.6x
announced 5/10/2017 via BNC Analysis

inVentiv Health, Inc. will be merged with INC Research, Inc.,

synopsis: INC Research Holdings, Inc., a leading global Phase I-IV Contract Research Organization ("CRO"), and inVentiv Health, Inc., a leading, global CRO and Contract Commercial Organization will merge. INC Research shareholders will own approximately 53 percent and inVentiv shareholders will own approximately 47 percent of the merged entity.
buyer: INC Research, Inc. (SYNH:$4,730.38)
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. "
target parent: Thomas H. Lee Partners, L.P.
target: inVentiv Health, Inc.
inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Their Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services.
price ($mm)[EV]
$2,453 [$4,552]
rev ($mm)
$2,156
EBITDA ($mm)
$306
EV / rev
2.1x
EV / EBITDA
14.9x
closed 10/3/2016 via BusinessWire

Quintiles Transnational Corp. merged with IMS Health Incorporated,

synopsis: Quintiles IMS Holdings, Inc. announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The merger creates a leading information and tech-enabled global healthcare service provider, and a full suite of end-to-end clinical and commercial offerings.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. They connect configurable SaaS applications to complex healthcare data in the IMS One™ cloud platform. "
target: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the world’s largest provider of biopharmaceutical development services and commercial outsourcing services. They help customers navigate the increasingly complex healthcare environment to improve efficiency and to deliver better healthcare outcomes.
price ($mm)
$8,750
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2009 via BusinessWire

PPD, Inc., acquired Excel PharmaStudies Inc.

synopsis: PPD, Inc. announced it has completed its acquisition of Excel PharmaStudies, Inc., one of the largest contract research organizations in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: Excel PharmaStudies Inc.
Excel PharmaStudies, Inc. is a full-service provider of clinical research, registration, biometrics, and training and consultation services. Excel is the leading CRO in China and operates 22 offices worldwide, with more than 300 staff members.
price ($mm)
$16
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/17/2009 via PR Newswire

Pierrel SpA, purchased US Operations from Encorium Group Inc.

synopsis: Encorium Group, Inc., a full service multinational clinical research organization, announced that is has completed the previously announced sale of the Company's U.S. business to Pierrel Research USA, Inc., a wholly-owned subsidiary of Pierrel SpA, an international contract research organization listed on Milano's Stock Exchange.
buyer: Pierrel SpA (PIELF:$0.00)
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use. "
seller: Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
price ($mm)[EV]
$0.08 [$2.58]
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 4/8/2009 via PR Newswire

Next Fuel, Inc., will acquire Clinical Trials of the Americas, Inc.

synopsis: Clinical Trials of America Inc. announced that it has entered into a binding letter of intent to sell shares equal to approximately 75% of its issued and outstanding shares to Next Fuel Inc., a developer of a proprietary "On Demand" Hydrogen Generation System.
buyer: Next Fuel, Inc.
Next Fuel Inc. is a developer of a proprietary "On Demand" Hydrogen Generation System that is used as fuel for Fuel Cells which produce electricity. "
target: Clinical Trials of the Americas, Inc.
Clinical Trials of the Americas, Inc. provides clinical trial investigator services in dedicated sites throughout the Americas. Initially, we intend to introduce our services in Central America.
price ($mm)
$0.29*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2009 via PR Newswire

ASG, Inc., acquired Ockham Development Group, Inc.

synopsis: ASG, Inc. a high-quality functional outsourcing and specialty staffing services group based in Cary, North Carolina - has acquired neighboring Ockham Development Group, Inc., a full-service contract research organization.
buyer: ASG, Inc.
ASG provides high-quality functional outsourcing and specialty staffing services to CROs, pharmaceutical, biotech and medical device companies that require clinical operations, GCP, GLP or GMP auditing, data management, statistical programming, biostatistics and medical writing solutions. "
target: Ockham Development Group, Inc.
Ockham Development Group Inc. is a privately held contract research organization headquartered in Cary, North Carolina.
price ($mm)
rev ($mm)
$12
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA

Like Envision Pharma, Inc.


read more

Envision Pharma, Inc.

Envision Pharma Group

Envision Pharma, Inc.

Envision Pharma, Inc.

The Edge Software Consultancy Ltd.

Longboat Clinical Ltd.

Laiya Consulting, Inc.

Aris Global LLC

SCYNEXIS, Inc.

MedSciNet

Greenphire, Inc

TrialTech Medical Inc.

Viedoc

Clinical Trial Connect, LLC

THREAD Research

OmniComm Systems, Inc.

Medidata

Custodix N.V.

GoBalto

Sylogent

read more

doDOC Corp.

Envision Pharma Group

90Ten

Envision Pharma, Inc.

Envision Pharma, Inc.

Envision Pharma, Inc.

read more

Envision Pharma, Inc.

Arrowhead Electronic Healthcare

Cognitive Drug Research, Ltd.

Healthcare Project Management

Envision Pharma, Inc.

BioCor LLC

BioNiche Global Learning

IQ Consultancy Group

MetaWorks, Inc.

MEDTAP International, Inc.

read more

Bio-Quant, Inc.

BioDuro, LLC

Boston Analytical

Celsis International

AAIPharma Services

MDS, Inc.

Prudentas, LLC

Vigiun

Patheon, Inc.

Applied Cell Sciences

Midwest BioResearch, LLC

Invicro, LLC

Aptuit, Inc.

PAREXEL International Corporation

inVentiv Health, Inc.

Quintiles Transnational Corp.

Excel PharmaStudies Inc.

Encorium Group Inc.

Clinical Trials of the Americas, Inc.

Ockham Development Group, Inc.

Geography
Matching Companies
Ticker: TSE:2413
 
 
 
 
 
 
 
 
M3.com
M3.com
M3.com is Japan's largest portal site dedicated to healthcare professionals. M3.com provides the latest medical news, overseas journal article summaries, and medical resources. The portal offers information on clinical trials and other services in the healthcare and pharmaceutical industries.
year
2019
rev ($mm)
$1,015.17
EBITDA ($mm)
$288.13
EBIT ($mm)
$275.64
Net Income ($mm)
$175.78
Employees
5165
  • drill down
  • watch
Ticker: TRHC
 
 
 
 
 
 
 
 
Tabula Rasa Healthcare
Tabula Rasa Healthcare
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk.
year
2018
rev ($mm)
$204.27
EBITDA ($mm)
$16.27
EBIT ($mm)
$1.63
Net Income ($mm)
Employees
952
  • drill down
  • watch
Ticker: ZMD
 
 
 
 
 
 
 
 
ZoomMed Inc.
ZoomMed Inc.
Zoommed Inc. develops and markets various computer applications for healthcare professionals in Canada. The company builds and operates the ZoomMed Communication Network, a clinical interoperable information exchange network between physicians and various other stakeholders of the healthcare sector.
year
2014
rev ($mm)
$6.08
EBITDA ($mm)
$2.65
EBIT ($mm)
$2.78
Net Income ($mm)
Employees
40
  • drill down
  • watch
Ticker: ASX:MDR
 
 
 
 
 
 
 
 
MedAdvisor Limited
MedAdvisor Limited
MedAdvisor is a world class medication management platform focused on addressing the gap and burden of medication adherence. The highly automated Australian software system connects patients to their local pharmacy, providing them with real time access to their personal medication records.
year
2016
rev ($mm)
$1.05
EBITDA ($mm)
($2.13)
EBIT ($mm)
($2.15)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: CHNG
 
 
 
 
 
 
 
 
Change Healthcare Corporation
Change Healthcare Corporation
Change Healthcare is a leading independent healthcare technology company that provides data and analytics-driven solutions to improve clinical, financial and patient engagement outcomes in the U.S. healthcare system.
year
2020
rev ($mm)
$1,646.91
EBITDA ($mm)
EBIT ($mm)
($155.95)
Net Income ($mm)
Employees
15000
  • drill down
  • watch
Ticker: AIM:MED
 
 
 
 
 
 
 
 
MedaPhor
MedaPhor
MedaPhor is a global provider of advanced ultrasound training simulators for medical professionals. Founded in 2004, they have headquarters in Cardiff, UK and San Diego, USA, and our customers are some of the world's leading medical institutions.
year
2017
rev ($mm)
$5.48
EBITDA ($mm)
($2.09)
EBIT ($mm)
($2.82)
Net Income ($mm)
Employees
31
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
Clarivate Analytics
Clarivate Analytics
Clarivate Analytics is a research analytics software company that provides subscription-based services in research and patent analytics. Organizations and researchers rely on the knowledge bases from Clarivate for information about pharmaceutical and biotech intelligence and IP management.
year
2021
rev ($mm)
$1,614.03
EBITDA ($mm)
$542.18
EBIT ($mm)
$84.79
Net Income ($mm)
Employees
8568
  • drill down
  • watch
Ticker: AIM:INS
 
 
 
 
 
 
 
 
Instem
Instem
Instem is a leading supplier of IT applications to the early development healthcare market delivering compelling solutions for data collection, management and analysis across the R&D continuum. Instem applications are in use by customers worldwide.
year
2020
rev ($mm)
$38.90
EBITDA ($mm)
$6.31
EBIT ($mm)
$5.20
Net Income ($mm)
$3.13
Employees
304
  • drill down
  • watch
Ticker: SYPT
 
 
 
 
 
 
 
 
Scrypt, Inc.
Scrypt, Inc.
Since 1998, Austin-based Scrypt, Inc. has been creating elegant document productivity tools for healthcare that eliminate manual processes and paper to save time and money. Scrypt has more than 30,000 customers across all 50 states.
year
2009
rev ($mm)
$0.27
EBITDA ($mm)
($0.85)
EBIT ($mm)
($0.91)
Net Income ($mm)
Employees
7
  • drill down
  • watch
Ticker: ENXTPA:CGM
 
 
 
 
 
 
 
 
Cegedim
Cegedim
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases.
year
2020
rev ($mm)
$592.02
EBITDA ($mm)
$54.63
EBIT ($mm)
$53.83
Net Income ($mm)
$12.91
Employees
5171
  • drill down
  • watch
Ticker: DATA
 
 
 
 
 
 
 
 
DATATRAK International, Inc.
DATATRAK International, Inc.
DATATRAK International, Inc. is a worldwide ASP for the EDC industry. The Company provides a suite of software products supporting the use of DATATRAK EDC(TM) and related services to the pharmaceutical, biotechnology, and medical device industries.
year
2012
rev ($mm)
$9.72
EBITDA ($mm)
($1.37)
EBIT ($mm)
($1.53)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: OM:RTC
 
 
 
 
 
 
 
 
Rethinking Care AB
Rethinking Care AB
Rethinking Care introduces a holistic concept in nursing & health, based on 3 interacting spheres of activity - "Software as a service", "Care as a service" & "Health as a service", based on a high level of competence in nursing & healthcare services as well as IT tools developed for health care.
year
2016
rev ($mm)
EBITDA ($mm)
EBIT ($mm)
Net Income ($mm)
Employees
  • drill down
  • watch
Ticker: INOV
 
 
 
 
 
 
 
 
Inovalon, Inc.
Inovalon, Inc.
Inovalon is a leading technology company that combines advanced cloud-based data analytics and data-driven intervention platforms to achieve meaningful insight and impact in clinical and quality outcomes, utilization, and financial performance across the healthcare landscape.
year
2017
rev ($mm)
$449.36
EBITDA ($mm)
$75.91
EBIT ($mm)
$27.16
Net Income ($mm)
$34.82
Employees
2119
  • drill down
  • watch
Ticker: NYSE:IQV
 
 
 
 
 
 
 
 
IQVIA
IQVIA
IQVIA Holdings Inc. provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services.
year
2018
rev ($mm)
$10,412.00
EBITDA ($mm)
$1,950.00
EBIT ($mm)
$809.00
Net Income ($mm)
$259.00
Employees
58000
  • drill down
  • watch
Ticker: AIM:CRON
 
 
 
 
 
 
 
 
Cronin Group PLC
Cronin Group PLC provides medical research and development services. The Company focuses on the discovery, development, and manufacture of small molecules and nano-materials utilizing proprietary chemistry. Cronin Group offers its services in the United Kingdom.
year
2018
rev ($mm)
EBITDA ($mm)
($2.29)
EBIT ($mm)
($2.34)
Net Income ($mm)
Employees
25
  • drill down
  • watch
Ticker: SYNH
 
 
 
 
 
 
 
 
INC Research, Inc.
INC Research, Inc.
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.
year
2021
rev ($mm)
$4,730.38
EBITDA ($mm)
$633.74
EBIT ($mm)
$407.86
Net Income ($mm)
$235.93
Employees
24310
  • drill down
  • watch
Ticker: ICLR
 
 
 
 
 
 
 
 
ICON Plc
ICON Plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development.
year
2015
rev ($mm)
$1,541.91
EBITDA ($mm)
$289.74
EBIT ($mm)
$234.82
Net Income ($mm)
$192.14
Employees
11200
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
CMIC Co., Ltd.
CMIC is a leading full-service CRO in Japan offering a wide range of services in clinical trials in Asia to both multi-national and Japanese pharma companies.
year
2019
rev ($mm)
$664.65
EBITDA ($mm)
$76.21
EBIT ($mm)
$43.15
Net Income ($mm)
$23.12
Employees
4962
  • drill down
  • watch
Ticker: PIELF
 
 
 
 
 
 
 
 
Pierrel SpA
Pierrel SpA
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use.
year
2008
rev ($mm)
$64.38
EBITDA ($mm)
($4.23)
EBIT ($mm)
($8.92)
Net Income ($mm)
Employees
504
  • drill down
  • watch
Ticker: ENCO
 
 
 
 
 
 
 
 
Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
year
2008
rev ($mm)
$35.91
EBITDA ($mm)
($5.19)
EBIT ($mm)
($6.89)
Net Income ($mm)
Employees
226
  • drill down
  • watch
Ticker: CRL
 
 
 
 
 
 
 
 
Charles River Laboratories International Inc.
Charles River Laboratories International Inc.
Charles River has been helping our global partners accelerate drug discovery and development by providing them with tailored research models and preclinical, clinical, support services.
year
2009
rev ($mm)
$1,202.55
EBITDA ($mm)
$282.48
EBIT ($mm)
$188.93
Net Income ($mm)
$114.44
Employees
8000
  • drill down
  • watch
Ticker: ENXTPA:ERF
 
 
 
 
 
 
 
 
Eurofins Group
Eurofins Group
Based in Luxembourg, Eurofins is a leading international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments.
year
2019
rev ($mm)
$5,244.00
EBITDA ($mm)
$922.65
EBIT ($mm)
$524.54
Net Income ($mm)
$224.34
Employees
47427
  • drill down
  • watch
Ticker: NEO
 
 
 
 
 
 
 
 
NeoGenomics Laboratories
NeoGenomics Laboratories
NeoGenomics is a leading cancer diagnostic reference laboratory. NeoGenomics offers testing services for oncologists, pathologists, and pharmaceutical centers. Their areas of expertise include cancer cytogenetics, hematologic and solid tumor FISH testing, molecular oncology tests, and more.
year
2020
rev ($mm)
$444.45
EBITDA ($mm)
$23.80
EBIT ($mm)
($11.92)
Net Income ($mm)
$4.17
Employees
1700
  • drill down
  • watch
Ticker: LH
 
 
 
 
 
 
 
 
LabCorp
LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp processes tests on approximately 470,000 specimens each day, applying advances in medicine and science to laboratory testing.
year
2021
rev ($mm)
$16,388.10
EBITDA ($mm)
$4,886.00
EBIT ($mm)
$4,358.30
Net Income ($mm)
$2,878.70
Employees
68780
  • drill down
  • watch